Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 AV-COVID-19 Vaccine Trial
NCT05007496Phase 2Completed
- Sponsor
- AIVITA Biomedical, Inc.
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of COVID-19 S-Vax loaded autologous dendritic cells in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by AIVITA Biomedical, Inc. Primary endpoint: Efficacy based on T-cell-induced immune response at 4 weeks. Started Apr 2021; status: completed.
02
Drugs
COVID-19 S-Vax loaded autologous dendritic cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05007496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007496.